This week's roundup of Houston innovators includes Kaitlyn Allen of MendIt, Miguel Calatayud of iwi, and Tatiana Fofanova of Koda Health. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to health tech — recently making headlines in Houston innovation.

Kaitlyn Allen, founder and chief strategy officer of MendIt

MendIt seeks to reduce textile waste by providing an easy-to-use app to make menders and customizers more accessible. Photo courtesy of MendIt

Kaitlyn Allen thought she had a great idea for a company — something that can help people repair clothing conveniently. And all of the pieces of the strategy already existed. There are plenty of seamstressing businesses around town, but not an easy way to navigate them. “

There’s a disconnect. There’s a market of people who potentially want to mend their clothes, but there’s no easy way of finding or accessing that service,” she says. “With this next generation, you need to meet them where they are.”

And where they are, Allen says, is on their phones.

MendIt is completing a pilot program with one mender — Connect Community in Gulfton area — in partnership with St. Luke's Gethsemane on Bellaire in Sharpstown. She also hopes to tap into a local artist who can help with customization — like embroidery, for instance. Click here to read more.

Miguel Calatayud, CEO of iwi

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

Miguel Calatayud feels like he has the perfect storm of a product. Not only does his company iwi's nutritional supplement have a sustainability focus, it's also just a very competitive product in the marketplace. The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2.

"We've been growing significantly for one main reason," Calatayud says. "It works."

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the Houston Innovators podcast. Click here to read more.

Tatiana Fofanova, co-founder and CEO of Koda Health

Tatiana Fofanova, co-founder and CEO of Koda, closed recent funding for the digital health startup. Image via LinkedIn

Tatiana Fofanova, Koda co-founder and CEO, has something to celebrate. The Houston-based startup announced this month that it raised $3.5 million in its latest seed round. The funding will be used to help the digital advanced care planning company double the size of its team in the next six months.

"Koda Health helps vulnerable people navigate and communicate difficult decisions about their health care journey. So, when hiring, we look for empathetic people who are phenomenal communicators," Tatiana Fofanova, Koda co-founder and CEO, says in a statement.

The Koda team will also use the funds to expand its operations to all 50 states. According to the statement, the team plans to focus on low-resource communities and operating in different languages. Click here to read more.

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

How this Houston innovator plans to make a sustainable impact — one algae farm at a time

Houston innovators podcast episode 120

If there's one thing Miguel Calatayud is passionate about it's conscious capitalism — and specifically that his company, iwi, a Houston-based food and nutritional supplement company, is striking the perfect balance between impact and profit.

The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2. Calatayud says the farms even area able to reuse 98 percent of the water involved in the process.

"In the past, you had to choose between making an impact and making a profit," Calatayud says on this week's episode of the Houston Innovators Podcast. "In our case, the way we built the company and the business model we put together, it's actually the opposite. The bigger the impact we make, the bigger the business we're creating."

With all this sustainability to boast about, Calatayud says it's not even the best part. Iwi's products, which include Omega-3 supplements, multivitamins, and even a forthcoming protein — all made from the farmed algae, are also very competitive products in the market.

"We've been growing significantly for one main reason," Calatayud says." It works."

"That's what's really driving the growth in the company because once a customer starts taking iwi, they don't go back to whatever they were taking before," Calatayud continues on the show.

Calatayud says iwi is ready to expand more internationally. The company recently closed an $8 million deal — $5.5 million in senior secured term debt and a $2.5 million direct equity investment — with GP Capital Partners, an investor and strategic partner for the company. The influx of funding will help iwi accelerate sales of its existing products and ramp up development, marketing, and growth of new protein-based product, according to the release. Iwi will also enter new international markets.

"What we are going to do with [GP] and other investors that we have is to take this brand to the next level," Calatayud says. "Last year, we grew 91 percent. This year, we are planning to grow around 200 percent."

Calatayud says the pond systems iwi operates are replicable, and as the company grows he could see building these types of algae farms across the world and even in the Middle East, creating jobs and opportunities globally.

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.